Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of TollB-001 Tablets in Patients With Systemic Sclerosis

NCT07745725 is registered in ClinicalTrials.gov with Toll Biotech Co. Ltd. (Beijing) as lead sponsor.

NCT NCT07745725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07745725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of TollB-001 Tablets in Patients With Systemic Sclerosis
Lead sponsor
Toll Biotech Co. Ltd. (Beijing)
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
February 29, 2028
Enrollment
36 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis (ssc)